title: Does imatinib mesylate therapy cause growth hormone deficiency?
abstract: OBJECTIVE
  The purpose of this study was to determine whether or not imatinib mesylate therapy induces growth hormone deficiency (GHD).
  
  
  METHODS
  Seventeen patients with chronic myloid leukemia (CML) were enrolled in the study. The glucagon stimulation test (GST), and standard deviation scores (SDSs) of insulin-like growth fac- tor 1 (IGF-I) and insulin-like growth factor binding protein (IGFBP-3) were used to determine GHD. The L-dopa test was performed on those with IGF-I SDSs above the -1.8 cut-off level.
  
  
  RESULTS
  Of the 17 patients in the study, 12 (70%) had severe GHD (serum GH level <3 microg/l after GST). IGF-I SDSs and IGFBP-3 SDSs were below -1.8 in 12 patients (70%) and below -0.9 in 10 subjects (58%). Four of the 5 remaining subjects with IGF-I SDS >-1.8 showed insufficient GH response to L-dopa stimulation. Nine subjects (52%) had both severe GHD based on GST response and IGF-I SDS below -1.8. If an IGF-I SDS cut-off value l<-3 were used,5 out of 17 subjects (30%) would be classified as GH deficient. These same patients also showed severe GHD based on GST response.
  
  
  CONCLUSIONS
  The data showed that a large number of patients on imatinib mesylate therapy had GH deficiency. A study involving a larger number of patients with a matched control group is needed to confirm the present observations.
authors: Division of Endocrinology and Metabolism, Bozyaka Training and Research Hospital, Izmir, Turkey. leventkebapcilar@yahoo.com
authors: L
authors: L
authors: Kebapcilar
authors: O
authors: O
authors: Bilgir
authors: I
authors: I
authors: Alacacioglu
authors: B
authors: B
authors: Payzin
authors: F
authors: F
authors: Bilgir
authors: P
authors: P
authors: Oner
authors: I
authors: I
authors: Sari
authors: M
authors: M
authors: Calan
authors: O
authors: O
authors: Binicier
mesh_terms: D000328:Adult; D001549:Benzamides; D005260:Female; D005934:Glucagon; D019382:Human Growth Hormone / Q000172:deficiency*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D007980:Levodopa; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D019382:Human Growth Hormone; D007980:Levodopa; D000068877:Imatinib Mesylate; D005934:Glucagon